APPLIED MOLECULAR TRANSPORT (AMTI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:AMTI • US03824M1099

0.263 USD
-0.04 (-14.3%)
At close: Dec 26, 2023
0.2629 USD
0 (-0.04%)
After Hours: 12/26/2023, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AMTI. AMTI was compared to 524 industry peers in the Biotechnology industry. AMTI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AMTI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • AMTI had negative earnings in the past year.
  • AMTI had a negative operating cash flow in the past year.
AMTI Yearly Net Income VS EBIT VS OCF VS FCFAMTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of AMTI (-373.95%) is worse than 97.30% of its industry peers.
  • The Return On Equity of AMTI (-461.67%) is worse than 80.61% of its industry peers.
Industry RankSector Rank
ROA -373.95%
ROE -461.67%
ROIC N/A
ROA(3y)-70.66%
ROA(5y)-82.71%
ROE(3y)-106.54%
ROE(5y)-110.95%
ROIC(3y)N/A
ROIC(5y)N/A
AMTI Yearly ROA, ROE, ROICAMTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

  • AMTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMTI Yearly Profit, Operating, Gross MarginsAMTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, AMTI has more shares outstanding
  • The debt/assets ratio for AMTI is higher compared to a year ago.
AMTI Yearly Shares OutstandingAMTI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M
AMTI Yearly Total Debt VS Total AssetsAMTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • AMTI has an Altman-Z score of -36.49. This is a bad value and indicates that AMTI is not financially healthy and even has some risk of bankruptcy.
  • AMTI has a worse Altman-Z score (-36.49) than 94.94% of its industry peers.
  • There is no outstanding debt for AMTI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -36.49
ROIC/WACCN/A
WACCN/A
AMTI Yearly LT Debt VS Equity VS FCFAMTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

  • AMTI has a Current Ratio of 4.95. This indicates that AMTI is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of AMTI (4.95) is comparable to the rest of the industry.
  • A Quick Ratio of 4.95 indicates that AMTI has no problem at all paying its short term obligations.
  • AMTI has a Quick ratio (4.95) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.95
Quick Ratio 4.95
AMTI Yearly Current Assets VS Current LiabilitesAMTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • AMTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.09%, which is quite impressive.
EPS 1Y (TTM)45.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 12.45% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.28%
EPS Next 2Y32.75%
EPS Next 3Y14.38%
EPS Next 5Y12.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMTI Yearly Revenue VS EstimatesAMTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M
AMTI Yearly EPS VS EstimatesAMTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AMTI. In the last year negative earnings were reported.
  • Also next year AMTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMTI Price Earnings VS Forward Price EarningsAMTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMTI Per share dataAMTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AMTI's earnings are expected to grow with 14.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.75%
EPS Next 3Y14.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AMTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

APPLIED MOLECULAR TRANSPORT

NASDAQ:AMTI (12/26/2023, 8:00:01 PM)

After market: 0.2629 0 (-0.04%)

0.263

-0.04 (-14.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09
Earnings (Next)03-07
Inst Owners0%
Inst Owner Change0%
Ins Owners1.85%
Ins Owner Change0%
Market Cap11.01M
Revenue(TTM)N/A
Net Income(TTM)-74.79M
Analysts43.33
Price Target1.02 (287.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-44.68%
Min EPS beat(2)-156.02%
Max EPS beat(2)66.67%
EPS beat(4)2
Avg EPS beat(4)-25.3%
Min EPS beat(4)-156.02%
Max EPS beat(4)66.67%
EPS beat(8)3
Avg EPS beat(8)-21.97%
EPS beat(12)5
Avg EPS beat(12)-11.57%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.43
OCFYN/A
SpS0
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -373.95%
ROE -461.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.66%
ROA(5y)-82.71%
ROE(3y)-106.54%
ROE(5y)-110.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.95
Quick Ratio 4.95
Altman-Z -36.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)159.65%
Cap/Depr(5y)173.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.85%
EPS Next Y70.28%
EPS Next 2Y32.75%
EPS Next 3Y14.38%
EPS Next 5Y12.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.85%
OCF growth 3YN/A
OCF growth 5YN/A

APPLIED MOLECULAR TRANSPORT / AMTI FAQ

Can you provide the ChartMill fundamental rating for APPLIED MOLECULAR TRANSPORT?

ChartMill assigns a fundamental rating of 2 / 10 to AMTI.


What is the valuation status for AMTI stock?

ChartMill assigns a valuation rating of 0 / 10 to APPLIED MOLECULAR TRANSPORT (AMTI). This can be considered as Overvalued.


How profitable is APPLIED MOLECULAR TRANSPORT (AMTI) stock?

APPLIED MOLECULAR TRANSPORT (AMTI) has a profitability rating of 0 / 10.


What is the expected EPS growth for APPLIED MOLECULAR TRANSPORT (AMTI) stock?

The Earnings per Share (EPS) of APPLIED MOLECULAR TRANSPORT (AMTI) is expected to grow by 70.28% in the next year.